AMERICAN NEUROTOLOGY SOCIETY
The Forty-Fourth Annual Meeting
May 29-30, 2009
JW Marriott Desert Ridge Resort
Phoenix, Arizona
Deadline for submission: Wednesday, October 15, 2008

Click here to download a MS WORD form of these instructions

Abstract Submission Instructions:

*The conflict of interest form must be completed at the time of submission of the abstract rather than only if the abstract is accepted. The purpose is to be sure that the SPC consider conflict of interest in the selection of abstracts. The ANS fax number is 217-438-6404. Please download the 09 ANS conflict of interest form by clicking here, file the MS Word document, print and fax when ready to submit abstract

The American Neurotology Society accepts on-line submission of abstracts to
www.americanneurotologysociety.com. The electronic version is not to contain any extraneous formatting instructions.

The ANS Scientific Program Committee will not consider abstracts that do not contain the required elements.

Abstracts must be structured according to Otology & Neurotology Guidelines for Authors

General Format:

A concise abstract of not more than 250 words or less is required for all original clinical and basic science contributions, including review articles. The ANS Scientific Program Committee for selection reviews all abstracts anonymously; please do not place any identifying information in the body of the abstract, such as referral to authorship or institution. Also, if the research in your paper is supported by a grant, or special financial arrangement, this must be identified. These should be organized according to the headings outlined below. The author(s) must accept sole responsibility for statements in their submitted abstract.

Choose an appropriate title reflecting the content of the abstract body. The title will appear in all publications if chosen for presentation. No changes to abstract will be accepted after October 15. Do not include the author’s name(s) in the abstract title or body.

List all authors in proper sequence (numbering 1, 2, 3, etc., if applicable) using first names, middle initials, and last names and exact degrees. Specify the primary author and the presenter of the abstract. Please specify a corresponding author to whom all correspondence about the abstract will be directed.

The ANS Scientific Program Committee will require a completed manuscript to the Otology & Neurotology Journal two to three weeks before the meeting so that the Chairperson of the Scientific Program Committee has an opportunity to review the manuscript for any commercial bias, conflict of interest, use of commercial names and any other identifying information that may conflict with the ACCME requirements. The program committee may revise submitted abstracts to enforce compliance with the ACCME requirements.

For clinical studies:

Objective: Brief, clear statement of the main goals of the investigation.
Study design: Specify the type of study-randomized, prospective double blind; retrospective case review; etc.
Setting: Primary care vs. Tertiary referral center; ambulatory vs. hospital; etc.
Patients: Primary eligibility criteria and key demographic features.
Intervention(s): Diagnostic, therapeutic, and/or rehabilitative.
Main outcome measure(s): The most essential criterion that addresses the study’s central hypothesis.
Results: Include statistical measures where appropriate.
Conclusions: Include only those directly supported by data generated from this study.

For basic science reports:

Hypothesis: Brief, clear statement of the main goals of the investigation.
Background: Concise orientation for the reader unfamiliar with this line of investigation.
Methods: Succinct summary of techniques and materials employed.
Results: Include statistical measures where appropriate.
Conclusions: Include only those directly supported by data generated from this study. Emphasize clinical relevance wherever possible.

For reviews and meta-analysis:

Objective: Brief, clear statement of the goals of the review.
Data sources: Specify database, search methodology, languages covered, and time frame.
Study selection: Criteria used to select articles for detailed review.
Data extraction: Means of assessing quality, validity, and comparability of extracted data.
Data synthesis: Specify statistical techniques used for data analysis.
Conclusions: Concise statement of primary inferences with any recommendations.
For All Human Studies: Indicate IRB Approval Number

Support/Acknowledgment:

Author Responsibility/Financial Disclosure/Conflict of Interest Form: All authors and contributing individuals are responsible for disclosing any potential conflict of interest. Conflict of interest of an individual has two components: 1) a financial relationship with a commercial interest (e.g., pharmaceutical company or medical device manufacturer); and, 2) the opportunity to influence content of a CME activity relevant to products and services of that commercial interest in order to comply with the ACCME requirements. At the time of the abstract submission, the primary authors and contributing individuals are required to sign a financial disclosur/conflict of interest form. The primary author accepts responsibility to secure conflict of interest/disclosure statements from all co-authors.

All authors must agree to disclose all non-FDA approved use of FDA approved drugs during the abstract submission process as well as the actual oral presentation in order to comply with the ACCME requirement. Completed forms must be faxed or e-mailed to the ANS Administrative Office. Click here to download the disclosure/conflict of interest document.

Copyright Transmittal: Abstracts are received with the understanding that they are not under simultaneous consideration by another publication and that they are original contributions that have not been previously published. Accepted abstracts become the permanent property of Otology & Neurotology and may not be published elsewhere without permission from Otology & Neurotology.

Publication Statement: The material in this abstract, (Name of Abstract) has not been submitted for publication, published, or presented previously at another national or international meeting and is not under consideration for presentation at another national or international meeting including another COSM society. The penalty for duplicate presentation/publication is prohibition of the author from presenting at a COSM society meeting for a period of three years.

Please read all instructions carefully. Failure to comply with the instructions could delay the review of or disqualify your abstract submission.

Abstract Form Information

The abstract form is located on a seperate page. AOL browser will not work well for this form. It is highly suggested not to use AOL to submit your abstract. You may run the risk of not having all important information cross over the server.

When listing additional authors, please list in numerical order. This pertains to the following:

1. Additional Authors Names
2. Additional Authors Addresses
3. Additional Authors Phone
4. Additional Authors fax

When completing your abstract submission form, please print the completed form before you submit. This will give you a text copy of your submission.

ALL AUTHORS AGREE TO COMPLY WITH POLICIES STATED ABOVE


When ready to proceed, please download the 2009 ANS Disclosure Statement Formy


Once the disclosure form has been completed and faxed, please click here to access the on-line abstract submission form.

** It has come to the attention of the webmaster and administrator, that the abstract submissions form webpage was not accessable to a few members. The occurances happened from the same institution. If this situation should happen, please contact your web administrator to make sure your web source is not protected from out-going email or form submissions. Thank you